Relationship between abundance of EGFR T790M mutation and efficacy of Almon-ertinib in the treatment of advanced non-small cell lung cancer patients
Objective To analyze the efficacy of Almonertinib in the treatment of advanced non-small cell lung cancer,and to explore the relationship between the abundance of EGFR T790M mutation and the efficacy of Almonertinib.Methods A retrospective analysis of 52 patients with stage Ⅲ and stage-Ⅳ non-small cell lung cancer accompanied with EGFR T790M muta-tion who were treated with Almonertinib and were resistant to EGFR TKI in the first/second generation was carried out.The Kaplan-Meier method and Cox model were used to analyze the prognosis,and the critical value of T790M mutation abundance related to the efficacy was explored.Results The ORR and DCR of the patients with lung cancer who received the treatment of Almonertinib were 48.1％and 94.2％respectively.The median abundance of T790M in peripheral blood was 1.94％.The cutoff value of abundance in patients treated with Almonertinib was 2.05％.Patients with mutation abundance≥2.05％were in-cluded in the high abundance group(25 cases),and patients with mutation abundance＜2.05％were included in the low abun-dance group(27 cases).The ORR of the high abundance group and the low abundance group was 84.0％and 14.8％respective-ly,and the PFS was 12.8 months and 7.2 months respectively,and the OS was 22.2 months and 18.3 months respectively.Cox regression analysis showed that gene type,sex,smoking history,and brain metastasis were not factors influencing PFS in pa-tients treated with Almonertinib,and the EGFR T790M mutation abundance in peripheral blood was an independent influencing factor of PFS.Conclusion The abundance of EGFR T790M mutation may predict the effective rate and survival of patients with NSCLC with advanced EGFR T790M mutation treated with Almonertinib.
万方数据
维普
